

# Phase I clinical study of SB17170 for the drug development for idiopathic pulmonary fibrosis

SPARK Biopharma



RESPIRATORY	Phase 1
Product Type	Small Molecule
Indication	Idiopathic pulmonary fibrosis (IPF)
Target	High Mobility Group Box 1 (HMGB1)
MoA(Mechanism of Action)	Inhibition of Alveolar macrophage & fibroblast, ECM deposition, and fibrosis in the lung parenchyma inhibit IPF disease progression.
Competitiveness	<ul style="list-style-type: none"> <li>• First-in –class product</li> <li>• Superior efficacy and low side effects compared to standard treatments</li> <li>• Improved compliance with once a day oral administration</li> <li>• Mono or combination treatment for patients refractory to Nintedanib</li> </ul>
Development Stage	Phase 1
Route of Administration	Oral